Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 1/20 | 0.74 |
| ▸ | CCKAR | P32238 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CCKBR | P32239 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21446808 | 0.87 | CCKAR (0.66) | NHERF1CCKARNPC1LMNARAB9A | |
| SCHEMBL1306446 | 0.85 | NHERF1 (0.74) | NHERF1CCKARNPC1LMNARAB9A | |
| SCHEMBL1308465 | 0.85 | NPC1 (0.59) | NHERF1CCKARNPC1LMNARAB9A | |
| SCHEMBL6716612 | 0.84 | CCKAR (0.62) | NHERF1CCKARNPC1LMNARAB9A | |
| SCHEMBL6834022 | 0.82 | NPC1 (0.55) | NHERF1CCKARNPC1LMNARAB9A | |
| SCHEMBL10562380 | 0.82 | NPC1 (0.66) | CCKARNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL19476087 | 0.82 | NPC1 (0.65) | CCKARNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL19476162 | 0.81 | NPC1 (0.64) | CCKARNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL19476097 | 0.81 | NPC1 (0.64) | CCKARNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL3995884 | 0.81 | CCKAR (0.58) | NHERF1CCKARNPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632911-B1 | METHOD FOR PREPARING ISOXAZINONE COMPOUND AND APPLICATION THEREOF | ZHEJIANG ZHUJI UNITED CHEMICALS CO LTD (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | NHERF1 1326/4885CCKAR 193/4885NPC1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.